Conference
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.
Authors
Spector N; Clementino NCD; Dorlhiac-Llacer PE; Leber B; Hughes TP; Cervantes F; Schwarer AP; Forrest DL; Kamel-Reid S; Bendit I
Volume
32
Pagination
pp. 7025-7025
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.7025
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X